Evidence map›Paper›PMID 8849230›Full record

ArticleAntimicrobial agents and chemotherapy1996

Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan.

H Ohno, H Koga, S Kohno, T Tashiro, K Hara

Abstract readComparative Study
In one paragraph

Article in Antimicrobial agents and chemotherapy, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed.

  1. Trial
  2. Identification of genetic mutations conferring tedizolid resistance in MRSA mutants.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Article
  3. Article
  4. The evolving biology ofFrontiers in cellular and infection microbiology · 2022
    Review
  5. Infection and drug resistance · 2022
    Article
  6. Article
  7. Low-Level Rifampin Resistance andJournal of clinical microbiology · 2021
    Article
  8. Infection and drug resistance · 2021
    Article
  9. Article
  10. Open forum infectious diseases · 2019
    Article
  11. Article
  12. Mutations ofEthiopian journal of health sciences · 2018
    Article
  13. Article
  14. Molecular characterisation of rifampicin-resistantAfrican journal of laboratory medicine · 2017
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

H OhnoSecond Department of Internal Medicine, Nagasaki University School of Medicine, Japan.
H Koga
S Kohno
T Tashiro
K Hara

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We analyzed the relationship between rifampin MICs and rpoB mutations of 40 clinical isolates of Mycobacterium tuberculosis. A point mutation in either codon 516, 526, or 531 was found in 13 strains requiring MICs of > or = 64 micrograms/ml, while 21 strains requiring MICs of < or = 1 microgram/ml showed no alteration in these codons. However, 3 of these 21 strains contained a point mutation in either codon 515 or 533. Of the other six strains requiring MICs between 2 and 32 micrograms/ml, three contained a point mutation in codon 516 or 526, while no alteration was detected in the other three. Our results indicate that the sequencing analysis of a 69-bp fragment in the rpoB gene is useful in predicting rifampin-resistant phenotypes.

Indexed as

Amino Acid SequenceAntitubercular AgentsBase SequenceHumansMicrobial Sensitivity TestsMolecular Sequence DataMycobacterium tuberculosisRifampinAntitubercular AgentsRifampin

Identifiers

PMID8849230
PMCPMC163262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.